All
Adding Cabtreo to the Acne Vulgaris Tool Box
Christopher Bunick, MD, PhD, reviews Cabtreo’s recent FDA approval and what the new triple-combination gel means for acne patients.
APG777: A Promising Breakthrough in IL-13 Targeted Therapy
The pharmacokinetic profile of APG777, characterized by an extended half-life, increased exposure, and reduced clearance compared to lebrikizumab, is promising for patients with IL-13-driven diseases.
40-GEP Identifies Patients Who Benefit Most From Adjuvant Radiation Therapy With Improved Metastasis-Free Survival of cSCC
The goal of Arron et al’s study was to determine if the 40-GEP test could identify high-risk cSCC patients who would benefit from ART in controlling metastatic disease progression.
Enhancing Skin Health With Macrocystis Pyrifera Ferment-Containing Creams
The positive outcomes observed in these cases underscore the potential for these products to revolutionize the way dermatology clinicians address visible signs of facial aging.
Overcoming Early Career Conundrums and Burnout With Muneeb Shah, DO
Shah is presenting alongside a panel of leading experts at Fall Clinical 2023.
A Deep Dive Into the Chronic Spontaneous Urticaria Armamentarium
Dawn Merritt, DO, and Mark Lebwohl, MD, took the stage to explain the history of CSU, the prevalence of testing and food avoidance, approved treatments, and monitoring treatment improvement for the condition.
2023 Fall Clinical Recap: Day 2
Catch up on coverage from the second day of the 2023 Fall Clinical Dermatology Conference.
Camp Wonder: Supporting Children With Life-Threatening Skin Diseases
Francesca Tenconi, president and CEO of Children’s Skin Disease Foundation and Camp Wonder, presented at Fall Clinical 2023 about the challenges of chronic skin conditions in children.
IDP-126 Approved by FDA for Treatment of Acne
The US Food and Drug Administration has approved IDP-126 gel for patients with acne.
FDA Issues Complete Response Letter for Dupilumab sBLA for Chronic Spontaneous Urticaria
The CRL states that additional efficacy data is needed in order to support approval.
2023 Inflammatory Disease Summit Recap
If you weren’t able to attend the 2023 Inflammatory Disease Summit or want to review our latest coverage and interviews, our full recap has you covered.
Breaking Down JAKs and TYKs
Kristine Kucera, PA-C, gave an in-depth overview of the JAK-STAT pathway at the 2023 Inflammatory Disease Summit.
Patient Perspective: Solutions for Relief After Years of Pain and Itch
Lisa Sanglay, FNP, and Lauren Miller, PA-C, interviewed a patient at IDS 2023 who used to have debilitating atopic dermatitis before seeing Sanglay for help and who prescribed upadacitinib.
Dermavant Shares Positive Phase 4 Tapinarof Data For Intertriginous Plaque Psoriasis
82.8% of adult patients with iPsO achieved an IGA score of 0 or 1 indicative of complete or almost complete lesion clearance.
Utilizing Biologics in the Management of Moderate to Severe Atopic Dermatitis
April Armstrong, MD, MPH, and Peter Lio, MD, explained the science behind how AD impacts quality of life and biologics on the market to enhance treatment plans.
80% of Patients With AD Demonstrated Sustained Skin Clearance With Lebrikizumab in 2-Year Data
Skin clearance, itch relief, and reduced severity of atopic dermatitis were sustained with monthly maintenance dosing.
Reviewing IDS 2023 and Psoriasis Clinical Cases With Tristan Hasbargen, PA-C
Hasbargen presented clinical cases alongside James Del Rosso, DO, at IDS 2023.
Data From Cohort of Janssen’s VISIBLE Trial Reveals Significant Skin Clearance in PsO Patients With Skin of Color
Topline results from the phase 3b trial revealed significant improvements in patients with skin of color whose psoriasis was treated with guselkumab.
Shawn Kwatra, MD: Managing Prurigo Nodularis With Biologics
Kwatra reviewed skin lesions in PN and important treatment considerations for patients at Fall Clinical.
2023 Fall Clinical Recap: Day 1
Catch up on coverage from the first day of the 2023 Fall Clinical Dermatology Conference and the Inflammatory Disease Summit.
QUIZ: What Percentage of Phase 1 Medications Become FDA Approved?
Andrea Nguyen, PA-C, reviewed types of clinical trials, phases, expenses, and more at the 2023 Inflammatory Disease Summit.
Neal Bhatia, MD: What Clinicians Need to Know About Actinic Keratosis
Bhatia also shared insights into ritlecitinib for alopecia areata at Fall Clinical 2023.
Psychosocial Impacts of Inflammatory Skin Conditions Must Be Addressed in Patient Care
Lauren Miller, PA-C, kicked off the inaugural 2023 Inflammatory Disease Summit by discussing the psychosocial impacts related to AD, PsO, and HS.
QUIZ: What Are the Major Cytokines Driving Atopic Dermatitis?
Test your knowledge on the foundation leading to the development of biologics to treat atopic dermatitis.
Aaron Farberg, MD, Gears Up For Early Career Advice and Melanoma Sessions at Fall Clinical
Farberg is looking forward to another year of top-notch presentations at Fall Clinical 2023.
Skin of Color Considerations in Aesthetics
Cheryl Burgess, MD, will share pearls on counseling patients on appropriate cosmetic procedures for their skin type, safety measures, and strategies to achieve desired outcomes.
What to Expect at the 2023 Inflammatory Disease Summit
The inaugural IDS meeting geared towards physician assistants and nurse practitioners begins the first day of Fall Clinical in Las Vegas.
Exploring the Best of Las Vegas During Fall Clinical
Looking to explore the city between Fall Clinical sessions or to extend your stay? Check out this top 10 list of the best Las Vegas has to offer in October.
What to Expect at the 2023 Fall Clinical Dermatology Conference
One of the largest dermatology meetings of the year kicks off today with an exciting line up of expert perspectives and clinical pearls. Here's what you can expect.
POLL: Are You Attending the 2023 Inflammatory Disease Summit?
Click here to answer if you're attending IDS 2023.
